Introduction: The fluocinolone acetonide (FA) intravitreal implant 0.59 mg (Retisert Ã’ , Bausch ? Lomb, Rochester, NY, USA) provides sustained release of FA directly to the vitreous cavity over a prolonged period of time. The purpose of this study was to evaluate the safety and efficacy of a 0.59-and 2.1-mg FA 